Zacks Small Cap Estimates VolitionRx Q3 Earnings

Key Points

• Zacks Small Cap forecasts VolitionRx's Q3 2025 earnings per share (EPS) to be ($0.07), with a full-year estimate of ($0.28) EPS.
• Insider buying was notable as CEO Cameron John Reynolds and Director Guy Archibald Innes each acquired 78,125 shares at $0.64, increasing their ownership significantly.
• The company's stock has a consensus rating of "Buy" with a target price of $3.50, despite recent trading down 3.7% to $0.66.

VolitionRx Limited (NYSE:VNRX - Free Report) - Analysts at Zacks Small Cap issued their Q3 2025 EPS estimates for VolitionRx in a research note issued to investors on Monday, August 25th. Zacks Small Cap analyst S. Ralston anticipates that the company will earn ($0.07) per share for the quarter. The consensus estimate for VolitionRx's current full-year earnings is ($0.28) per share. Zacks Small Cap also issued estimates for VolitionRx's Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.25) EPS.

A number of other equities analysts also recently commented on the stock. D. Boral Capital reissued a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a research note on Friday, August 15th. Wall Street Zen initiated coverage on shares of VolitionRx in a research note on Thursday, May 15th. They issued a "sell" rating on the stock. Finally, Jones Trading raised shares of VolitionRx to a "strong-buy" rating and set a $3.00 target price on the stock in a research note on Tuesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $3.50.

VolitionRx Trading Down 3.7%

Shares of VNRX stock opened at $0.66 on Wednesday. The company's fifty day simple moving average is $0.71 and its 200-day simple moving average is $0.60. VolitionRx has a 52 week low of $0.40 and a 52 week high of $0.94. The company has a market cap of $71.01 million, a PE ratio of -1.83 and a beta of 1.26.

Insider Buying and Selling

In other news, CEO Cameron John Reynolds acquired 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The shares were bought at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 2,609,847 shares of the company's stock, valued at approximately $1,670,302.08. This trade represents a 3.09% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Guy Archibald Innes acquired 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the purchase, the director directly owned 966,814 shares of the company's stock, valued at approximately $618,760.96. This trade represents a 8.79% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 188,750 shares of company stock worth $118,175 in the last quarter. Insiders own 10.40% of the company's stock.

Institutional Trading of VolitionRx

A number of hedge funds and other institutional investors have recently made changes to their positions in VNRX. Lagoda Investment Management L.P. increased its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after buying an additional 1,481,000 shares during the last quarter. Armistice Capital LLC increased its stake in shares of VolitionRx by 3.5% in the second quarter. Armistice Capital LLC now owns 8,493,074 shares of the company's stock worth $6,455,000 after buying an additional 286,644 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRx in the second quarter worth $52,000. Millennium Management LLC bought a new stake in shares of VolitionRx in the fourth quarter worth $36,000. Finally, Silverberg Bernstein Capital Management LLC increased its stake in shares of VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after buying an additional 60,209 shares during the last quarter. Institutional investors own 8.09% of the company's stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.